Andy Cohen said he lost “a good chunk of weight” this summer after he began "micro-dosing" a GLP-1 weight-loss medication, the host revealed on a recent episode of his SiriusXM program.
Cohen, 54, told listeners on Tuesday that he had been "really unhappy with" his weight and that his doctor had recommended a GLP-1 last year to address weight concerns and to treat plaque in his arteries and high blood pressure. He did not disclose which specific medication he was taking, but described it as "a medication that actually is beneficial to a lot of elements of health and I finally said yes."
Cohen said the drug helped curb his snacking, which he identified as his biggest challenge during what he called a "pretty rigorous" fitness regimen. "I have to say, it really helped me with cravings," he said, noting that the medication made it easier for him to be disciplined with diet and exercise. He added that his appetite returned after the micro-dose but that the experience "caused me to reframe my relationship with food." He said the course of treatment was managed under the care of a doctor and in conjunction with a trainer.
The host also acknowledged his relative privilege in being able to try the drug through insurance. He said he chose to disclose his use because it would be "completely hypocritical not to share" after spending two decades asking guests on his shows about their body regimens.
Cohen is part of a growing list of public figures who have discussed using GLP-1 receptor agonists such as Ozempic and Mounjaro or other prescription options. Several cast members from the "Real Housewives" franchises have publicly discussed their experiences, and in July Serena Williams told People she used a GLP-1 medication distributed by Ro to lose more than 30 pounds, saying, "I feel great. I feel really good and healthy. I feel light physically and light mentally."
The rising visibility of GLP-1 use among celebrities has coincided with increased public interest in the medications, which were developed to treat type 2 diabetes and have been prescribed off-label or for weight management under medical supervision. Cohen emphasized that his treatment was undertaken with medical oversight.
On his program, Cohen framed the choice to speak publicly as part of normalizing conversations about health and medical treatments. He described the medication as "revolutionary" for some patients and reiterated that his decision followed consultation with a physician. He did not provide a timeline for how long he had been on the drug beyond saying he started this summer.
Cohen's disclosure adds to an ongoing public discussion about the use, access and effects of GLP-1 medications as celebrities and non-celebrities alike report weight-loss outcomes and lifestyle changes while noting the importance of clinician guidance.